125742 45 S211 M5 c4591001 interim ado mth6 summary of changes

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 12 15 Documents

1

Document text

CLINICAL STUDY REPORT AMENDMENT 
SUMMARY OF CHANGES 
Protocol Number: C4591001
CONFIDENTIAL
Page 1Study  Report Title: Interim Report –Adolescent 6- Month Update : 
A Phase 1/2/3, Placebo -Controlled, 
Randomized, Observer -Blind, Dose -Finding 
Study  to Ev aluate the Safety , Tolerability , 
Immunogenicit y, and Efficacy of SARS -CoV-
2 RNA Vaccine Candidates Agains t 
COVID -19 in Healthy  Individuals
Clinical Study  Report Date: 03December 2021
Date o f Form Completion: 10December 2021
The Clinical Study  Report (CSR) was amended to make the changes noted below.
Section Change
CSR Title Pag eand CSR 
SynopsisCSR Title Page and CSR Synopsis Report Date and Previous 
Report Date were updated.  
Section 11.1.1.1.1, Table 14 The data values for the comorbidities and obese subgroups 
were flipped with e ach other. Table 14 was updated to correct 
thesevalues .
Section 14, Supplemental 
Tables 14.12 and 14.13The data values for the comorbidities and obese subgroups 
were flipped with each other. Supplemental Tables 14.12 and 
14.13 were updated to correct th ese values.
090177e198d7ba4a\Approved\Approved On: 13-Dec-2021 02:30 (GMT) 
FDA-CBER-2022-5812-0228962